Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension

Hypertension Research

Volumn 34, Issue 3, 2011, Pages 331-335

  Kato, Johji ^a   Yokota, Naoto ^a   Tamaki, Noboru ^a   Kariya, Sumito ^a   Kita, Toshihiro ^b   Ayabe, Takao ^a   Eto, Tanenao ^c   Kitamura, Kazuo ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Miyazaki Prefectural Health Foundation   (Japan)

Author keywords

ARB; CCB; combination therapy; diuretics; elderly

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; OLMESARTAN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CERVICAL SPONDYLOSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; ELDERLY CARE; FEMALE; FRACTURE; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIONAL VERTIGO; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, HDL; CREATININE; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 79952425626     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.233     Document Type: Article

References (24)

1. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32: 3-107.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25: 1105-1187. (Pubitemid 46924065)
3. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, for National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36: 646-661.
4. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S,Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351: 1755-1762. (Pubitemid 28269185)
5. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006;29(Suppl): S1-S105.
6. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358: 1887-1898. (Pubitemid 351620109)
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-1041.
8. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359, 995-1003.
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-869.
10. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro- flumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366: 895-906.
11. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 2009;13: 537-566.
12. Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996;81: 180-183. (Pubitemid 26035022)
13. Kato J, Kitamura K, Uemura T, Kuwasako K, Kita T, Kangawa K, Eto T. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 2002;25: 887-892. (Pubitemid 36024645)
14. Zhou BF, Stamler J, Dennis B, Moag-Stahlberg A, Okuda N, Robertson C, Zhao L, Chan Q, Elliott P, for the INTERMAP Research Group. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens 2003;17: 623-630. (Pubitemid 37265100)
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288: 2981-2997.
16. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, the J-LIT Study Group. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002;66: 1087-1095. (Pubitemid 35416312)
17. Nakaya N, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, the J-LIT Study Group. Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: subanalysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 2005;69: 1016-1021. (Pubitemid 41603084)
18. Kaplan NM, Victor RG. Kaplan's Clinical Hypertension, 10th edn. Lippincott Williams &Wilkins: Philadelphia, 2010, pp 192-273.
19. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, On behalf of the GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73: 1303-1309. (Pubitemid 351693145)
20. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359: 2417-2428.
21. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos- Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, for the ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375: 1173-1181.
22. Kita T, Yokota N, Ichiki Y, Ayabe T, Etoh T, Tamaki N, Kato J, Eto T, Kitamura K, for the PALM-1 study investigators. One-year effectiveness and safety of open-label losartan/ hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res 2010;33: 320-325.
23. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51: 393-398. (Pubitemid 351159955)
24. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Saito I, Shimada K, on behalf of the COLM study investigators. Rationale, study design and implementation of the COLM study: the combination of olmesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009;32: 163-167.